FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4237996827> ?p ?o ?g. }

• W4237996827 abstract "Purpose: The superiority of chemoradiotherapy (CRT) over radiation alone in locally advanced non-small cell lung cancer (NSCLC) has been proven, but the relative merits of a concurrent schedule versus their sequential administration are less clear. This study compared the safety and efficacy of concurrent and sequential CRT, with chemotherapy (CT) consisting of a cisplatin and vinorelbine regimen, in patients with locally advanced NSCLC. Patients and methods: One hundred and two previously untreated patients (aged 42–75 years) with locally advanced, stage IIIA (n=15) or stage IIIB (n=87) NSCLC were entered into the study. The CT schedule consisted of up to four cycles of cisplatin 80 mg/m2 on day 1, and vinorelbine 25 mg/m2 at the first and fourth cycles (12.5 mg/m2 during the 2nd/3rd cycles) on days 1, 8, 15 of a 28-day cycle. Radiotherapy (RT) was prescribed at a dose of 60 Gy/30 fractions, given as five fractions per week for 6 weeks. In the concurrent arm (arm A), RT was started on day 4 of cycle 2; whilst in the sequential arm (arm B), RT started within 2 weeks after completion of CT. Fifty-two patients were randomized to concurrent treatment and 50 to the sequential schedule. Results: Overall survival was significantly longer in arm A (median survival 16.6 months) versus arm B (median survival 12.9 months) (P=0.023 by means of log-rank test; hazard ratio HR=0.61, 95% CI of HR (0.39–0.93)), and time to progression (TTP) was also significantly longer in arm A (median time to progression 11.9 months) versus arm B (median time to progression 8.5 months) (P=0.024 by means of log-rank test; HR=0.62, 95% CI of HR (0.38–0.93)). Ninety-eight patients were evaluable for response and 101 for toxicity. The overall response rate was significantly higher in arm A, 80% (with 21% complete response (CR)) compared with 47% (with 17% CR) in arm B (P=0.001 by means of χ2-test). WHO grade 3 or 4 toxicity was more frequent in arm A than in arm B, with a significantly greater incidence of leucopenia (53% versus 19%, P=0.009 by means of χ2 test) and nausea/vomiting (39% versus 15%, P=0.044 by means of χ2 test). There were no treatment related deaths. Conclusion: In this study population, concurrent CRT demonstrated significant benefit in terms of response rate, overall survival and time to progression over sequential CRT. The concurrent CRT schedule was associated with higher toxicity; however, the adverse event profile was acceptable in both arms." @default.
• W4237996827 created "2022-05-12" @default.
• W4237996827 creator A5088240085 @default.
• W4237996827 date "2004-05-01" @default.
• W4237996827 modified "2023-10-01" @default.
• W4237996827 title "Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study" @default.
• W4237996827 doi "https://doi.org/10.1016/s0169-5002(04)00135-7" @default.
• W4237996827 hasPublicationYear "2004" @default.
• W4237996827 type Work @default.
• W4237996827 citedByCount "0" @default.
• W4237996827 crossrefType "journal-article" @default.
• W4237996827 hasAuthorship W4237996827A5088240085 @default.
• W4237996827 hasConcept C126322002 @default.
• W4237996827 hasConcept C126894567 @default.
• W4237996827 hasConcept C141071460 @default.
• W4237996827 hasConcept C143998085 @default.
• W4237996827 hasConcept C2776256026 @default.
• W4237996827 hasConcept C2776694085 @default.
• W4237996827 hasConcept C2778239845 @default.
• W4237996827 hasConcept C2778424827 @default.
• W4237996827 hasConcept C2780350996 @default.
• W4237996827 hasConcept C2781413609 @default.
• W4237996827 hasConcept C509974204 @default.
• W4237996827 hasConcept C71924100 @default.
• W4237996827 hasConceptScore W4237996827C126322002 @default.
• W4237996827 hasConceptScore W4237996827C126894567 @default.
• W4237996827 hasConceptScore W4237996827C141071460 @default.
• W4237996827 hasConceptScore W4237996827C143998085 @default.
• W4237996827 hasConceptScore W4237996827C2776256026 @default.
• W4237996827 hasConceptScore W4237996827C2776694085 @default.
• W4237996827 hasConceptScore W4237996827C2778239845 @default.
• W4237996827 hasConceptScore W4237996827C2778424827 @default.
• W4237996827 hasConceptScore W4237996827C2780350996 @default.
• W4237996827 hasConceptScore W4237996827C2781413609 @default.
• W4237996827 hasConceptScore W4237996827C509974204 @default.
• W4237996827 hasConceptScore W4237996827C71924100 @default.
• W4237996827 hasLocation W42379968271 @default.
• W4237996827 hasOpenAccess W4237996827 @default.
• W4237996827 hasPrimaryLocation W42379968271 @default.
• W4237996827 hasRelatedWork W2006192033 @default.
• W4237996827 hasRelatedWork W2056002207 @default.
• W4237996827 hasRelatedWork W2085142786 @default.
• W4237996827 hasRelatedWork W2170498496 @default.
• W4237996827 hasRelatedWork W2277416945 @default.
• W4237996827 hasRelatedWork W2288689888 @default.
• W4237996827 hasRelatedWork W2367461116 @default.
• W4237996827 hasRelatedWork W2377331194 @default.
• W4237996827 hasRelatedWork W2381460883 @default.
• W4237996827 hasRelatedWork W2381673287 @default.
• W4237996827 isParatext "false" @default.
• W4237996827 isRetracted "false" @default.
• W4237996827 workType "article" @default.